Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

A recent cohort study identifies a cortical biomarker signature, combining sensorimotor peak alpha frequency and corticomotor ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...

A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain ...

In an era where health and wellness are prioritized more than ever, the quest for effective natural remedies has led many to ...

A novel biomarker signature that assessed cortical activity predicted individual pain sensitivity, the PREDICT validation ...

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.